Selank 10mg
LatestLOT SLK0002
99.49%
HPLC purity · meets spec
- Labeled
- 10mg
- Measured
- 10.62mg
- Identity
- Confirmed
- Heavy metals
- Not Detected
- Sterility
- No Growth
- Endotoxin
- < 0.05 EU/mL
- Tested
- Jul 30, 2026
8 assays passed · ISO/IEC 17025 accredited
⚠️ FOR RESEARCH PURPOSES ONLY — This compound is not FDA approved. All data presented is from clinical trials for educational reference.
Cognitive & Anxiolytic Peptide
SELANK
TP-7SelancThr-Lys-Pro-Arg-Pro-Gly-ProCAS: 129954-34-3
A 7-amino acid synthetic heptapeptide derived from tuftsin that modulates GABAergic neurotransmission and BDNF expression, studied for anxiolytic and nootropic effects in clinical research. Premium Research Peptide.
Mass
Quantity
1
$29.95
Quantity
1
$29.95
Order by 12pm PT / 3pm ET to ship same day
Tue, Aug 18 - Fri, Aug 21
Overnight shipping available
We accept
SELANK$29.95
Free shippingon orders over $150
Damageprotection
Secure checkout256-bit SSL
Verified Test Results
Every batch, independently verified.
Each batch is analyzed by an ISO/IEC 17025 accredited third-party laboratory before it ships. This is the released report for the current batch, exactly as the lab signed it.
ILSILS LaboratoriesIndependent, ISO/IEC 17025 accredited
Certificate of Analysis
99.49%
Purity by HPLC
- Lot
- SLK0002
- Tested
- Jul 30, 2026
- Labeled
Third-party verified
Certificate of Analysis
Every lot is HPLC-tested at an ISO/IEC 17025-accredited lab. Open any batch's certificate below.
Compound Information
Technical specifications
Molecular Profile
What Is Selank?
Synthetic heptapeptide analog of tuftsin, an immunomodulatory tetrapeptide derived from IgG
HeptapeptideTuftsin Analog
TypeSynthetic heptapeptide
CAS Number129954-34-3
Molecular FormulaC33H57N11O9
Molecular Weight751.9 g/mol
Amino Acids7 residues
SequenceThr-Lys-Pro-Arg-Pro-Gly-Pro
Storage Requirements
Stability Information
Handle with care to maintain potency
Light sensitiveTemperature sensitive
Lyophilized (powder)
-20°C•protect from light
Reconstituted
2-8°C
Nasal spray (0.15%)
2-8°C•30 days after opening
Development Status
Regulatory Information
Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences
DeveloperRussian Academy of Sciences
CollaboratorV.V. Zakusov Institute
ApprovalRussia (2009), Ukraine
IndicationGeneralized Anxiety Disorder
US StatusNot FDA-approved
Formulation0.15% nasal drops (Rx in Russia)
Sources & References
Peer-reviewed research
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
2008•PMID: 18454096
Zozulia AA, Neznamov GG, Siuniakov TS, et al.
View Source
Behavioural NeurologyPeptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
2017•DOI: 10.1155/2017/5091027•PMID: 28280289
Kasian A, Kolomin T, Andreeva L, et al.
View Source
⚠️Important Research Notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
-01KWCZ4XZMAQQGZEYBXD5TF8AA.png&w=3840&q=75&dpl=dpl_4ZhY3y4gwE3mhr69cPxaqDoTowmz)
